The clinical, genetic or biological variables which regulate long-term efficacy of cholinesterase inhibitors (ChEIs) in Alzheimer disease (AD) are still unknown and it is not possible to predict who will benefit from the treatment. In this study we showed that high cholesterol levels correlated with faster decline at 1-year follow-up in AD patients on ChEIs. These findings suggest that serum cholesterol is a modulating factor of treatment response and additional therapies aimed at reducing treatable high cholesterol levels may represent an alternative strategy to improve ChEIs efficacy and slow down disease progression over time. © 2003 Elsevier Science Ireland Ltd. All rights reserved.
|Titolo:||Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease|
DILUCA, MONICA MARIA GRAZIA (Penultimo)
|Parole Chiave:||Alzheimer disease; Cholinesterase inhibitors; Serum cholesterol; Treatment efficacy|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||2003|
|Digital Object Identifier (DOI):||10.1016/S0304-3940(03)00336-7|
|Appare nelle tipologie:||01 - Articolo su periodico|